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case report
Resistance to octreotide 
LAR in acromegalic patients 
with high SSTR2 expression: 
analysis of AIP expression
Resistência ao octreotide LAR em pacientes acromegálicos com 
alta expressão do SSTR2: avaliação da expressão do AIP
Leandro Kasuki1,2, Leandro M. Colli3, Paula C. L. Elias3, 
Margaret de Castro3, Mônica R. Gadelha1
SUMMARY
We present here the clinical and molecular data of two patients with acromegaly treated with 
octreotide LAR after non-curative surgery, and who presented different responses to therapy. 
Somatostatin receptor type 2 and 5 (SSTR2 and SSTR5), and aryl hydrocarbon receptor-inter-
acting protein (AIP) expression levels were analyzed by qPCR. In both cases, high SSTR2 and 
low SSTR5 expression levels were detected; however, only one of the patients achieved disease 
control after octreotide LAR therapy. When we analyzed AIP expression levels of both cases, the 
patient whose disease was controlled after therapy exhibited AIP expression levels that were 
two times higher than the patient whose disease was still active. These two cases illustrate 
that, although the currently available somatostatin analogs bind preferentially to SSTR2, some 
patients are not responsive to therapy despite high expression of this receptor. This difference 
could be explained by differences in post-receptor signaling pathways, including the recently 
described involvement of AIP. Arq Bras Endocrinol Metab. 2012;56(8):501-6
SUMÁRIO
Apresentamos os dados clínicos e moleculares de dois pacientes com acromegalia tratados 
com octreotide LAR após cirurgia não curativa, com diferentes respostas a essa terapia medica-
mentosa. As expressões do receptor de somatostatina tipo 2 e 5 (SSTR2 e SSTR5) e da proteína 
de interação com o receptor aril hidrocarbono (AIP) foram analisadas por qPCR. Em ambos 
os casos, foi encontrada uma expressão elevada de SSTR2 e baixa do SSTR5. No entanto, o 
controle da doença foi obtido após tratamento com octreotide LAR em apenas um dos pacien-
tes. Quando analisamos a expressão do AIP em ambos os casos, o paciente cuja doença foi 
controlada após a terapia medicamentosa apresentou uma expressão duas vezes maior do que 
a do paciente não controlado com o tratamento. Conclui-se que esses dois casos ilustram que, 
embora os análogos de somatostatina atualmente disponíveis se liguem preferencialmente 
ao SSTR2, alguns pacientes não respondem ao tratamento, apesar de uma elevada expressão 
desse receptor. Isso poderia ser explicado por alterações nas vias de sinalização pós-receptor, 
incluindo o envolvimento recentemente descrito da AIP. Arq Bras Endocrinol Metab. 2012;56(8):501-6
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INTRODUCTION 
The currently available somatostatin analogs (SSAs) octreotide and lanreotide are considered corner-
stones of the medical treatment for acromegaly (1,2). 
SSAs act mainly by binding to somatostatin receptor 
type 2 (SSTR2) (3). Thus, as expected, SSTR2 expres-
sion is a predictor of the response to these drugs, and 
patients harboring tumors that present low SSTR2 ex-
pression are resistant to SSAs (4,5). However, in some 
cases, acromegaly is not controlled with SSAs therapy 
despite a high SSTR2 expression level in the somatotro-
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pinoma, indicating that although the presence of a high 
SSTR2 expression is essential for the action of SSAs, 
other factors, such as post-receptor signaling pathways, 
may be involved in the lack of response to SSAs in tu-
mors presenting high expression of SSTR2 (5). 
Recently, germline mutations in the aryl hydrocar-
bon receptor-interacting protein (AIP) gene have been 
described in the setting of familial isolated pituitary ad-
enoma, and in seemingly sporadic young-onset pitu-
itary adenoma patients (6,7). The patients harboring 
mutations in the AIP gene present worse response to 
SSAs therapy (8,9). Although somatic mutations have 
not been described, some sporadic tumors present low 
AIP expression, and patients harboring tumors with 
this feature have a lower probability of acromegaly con-
trol with SSAs treatment (10-12). Moreover, SSAs in-
crease AIP expression, and, although the mechanism 
of action of SSAs is not completely understood, this 
feature appears to be important in the mechanism of 
action of this drug class (13).
To illustrate the importance of AIP expression in 
the response to SSAs therapy in acromegaly, we de-
scribe two patients whose somatotropinomas presented 
high SSTR2 expression levels, but exhibited different 
responses to octreotide LAR (OCT-LAR) treatment.
SUBJECTS AND METHODS
This study was approved by the Ethics Committees 
of the Clementino Fraga Filho University Hospital/
Medical School, Universidade Federal do Rio de Janei-
ro, and Hospital das Clínicas/Ribeirão Preto Medical 
School, Universidade de São Paulo. All subjects signed 
an informed consent before entering the study. 
CASE REPORTS
Case 1
A 37 year-old female acromegalic patient was diag-
nosed due to a history of acral enlargement and amen-
orrhea. At diagnosis, she presented basal growth hor-
mone (GH) level of 185.0 ng/mL and insulin-like 
growth factor type I (IGF-I) level of 1,470 ng/mL 
(age-adjusted normal range, 106-277). Anterior pi-
tuitary workup revealed normal basal serum cortisol 
(9.0 μg/dL); no hypothyroidism (TSH: 0.36 IU/mL; 
free T4:1.0 ng/dL), and slightly elevated prolactin of 
41.0 ng/dL with LH and FSH levels in the normal 
range (1.0 and 2.2 mU/mL, respectively). Magnetic 
resonance imaging (MRI) of the sellar region revealed 
a 3.0 x 2.1 x 2.5 cm sellar tumor with supra-sellar 
extension and invasion of the cavernous sinus (Figure 
1). Examination of her visual field was normal. The 
patient was submitted to transesphenoidal surgery, 
but remained with active disease after the surgical pro-
cedure. Anatomopathological study revealed a pitu-
itary adenoma with positive immunostaining only for 
GH. Therefore, treatment with OCT-LAR was initi-
ated at a dosage of 20 mg every four weeks, with con-
trol of the hormone levels after six months of medical 
therapy, with no further need for dose adjustment. A 
residual sellar lesion of 1.5 cm was present at MRI af-
ter transesphenoidal surgery and remained unchanged 
during follow-up. GH and IGF-I levels at diagnosis, 
post-surgery, and after OCT-LAR therapy are shown 
in table 2.
Case 2
A 46-year-old male patient presented history of asthe-
nia, hyperhidrosis, hand edema, and decreased libido 
that had started three years before. At initial labo-
ratory evaluation, he presented hyperprolactinemia 
(prolactin, 91.4 ng/mL; normal range, 4.1-17.7), 
central hypothyroidism (free T4, 0.59 ng/dL; nor-
mal range, 0.8-1.9; TSH, 4.1 mcU/mL), GH level 
of 3.41 ng/mL, and IGF-I level of 224 ng/mL (age-
adjusted normal range, 101-267). After treatment for 
central hypothyroidism, GH level was 15.6 ng/mL, 
and IGF-I level was 555 ng/mL. MRI of the sellar 
region showed a 2.6 x 2.5 x 2.6 cm intra-sellar lesion 
with infra-sellar and right cavernous sinus extension 
involving the right internal carotid artery (Figure 2). 
The patient was submitted to surgery; however, to-
tal macroscopic resection was not achieved, although 
he exhibited an improvement in GH and IGF-I lev-
els (4.0 ng/mL and 411 ng/mL, respectively). The 
anatomopathological study revealed a pituitary ad-
enoma with positive immunostaining for GH and 
prolactin. After surgery, treatment with OCT-LAR 
was initiated at a dosage of 20 mg every four weeks, 
with posterior up-titration to 30 mg every four weeks, 
without controlling the disease after one year of trea-
tment. A residual lesion in the right cavernous sinus 
of 1.0 cm was present at MRI after transesphenoidal 
surgery and remained unchanged during follow-up. 
GH and IGF-I levels at diagnosis, three months post-
surgery and after six months of OCT-LAR therapy are 
shown in table 3.
AIP and octreotide LAR response
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Table 1. Taqman® assays
Gene Assays (TaqMan® Applied Biosystems)
AIP Hs_00610222_m1*
SSTR2 Hs_00990356_m1
SSTR5 Hs00990408_s1
TBP Hs_00427621_m1*
GUS Beta Hs_00939627_m1*
PGK1 Hs_99999906_m1
AIP: aryl hydrocarbon receptor-interacting protein; SSTR2: somatostatin receptor type 2; TBP: 
TATA box-binding protein; GUSβ: β-glucuronidase; PGK1: phosphoglycerate kinase 1.
Figure 1. Magnetic resonance imaging of the sellar region (case 1).
Magnetic resonance imaging of the sellar region (A: coronal T1-weighted 
with gadolinium enhancement; B: Sagittal T1-weighted with gadolinium 
enhancement) revealing a 3.0 x 2.1 x 2.5 cm sellar tumor with infra- and 
supra-sellar extension with invasion of the cavernous sinus. 
A A
B B
Table 2. Laboratory evaluation of patient 1
GH (ng/mL) IGF-I (ng/mL) NR: 106-277
Diagnosis 185.0 1470
Post-surgery (3 months) 77.0 479
Octreotide LAR 20 mg (6 months) 0.8 166
Octreotide LAR 20 mg (36 months) 0.7 104
Values of growth hormone (GH) and insulin-like growth factor type I (IGF-I) at diagnosis, 
after surgery and after medical therapy in patient 1; NR: normal range.
Figure 2. Magnetic resonance imaging of the sellar region (Case 2).
Magnetic resonance imaging of the sellar region (A: coronal T1-weighted 
with gadolinium enhancement; B: Sagital T1-weighted with gadolinium 
enhancement) showing a 2.6 x 2.5 x 2.6 cm intra-sellar lesion with infra-
sellar and right cavernous sinus extension. 
AIP and octreotide LAR response
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Analysis of AIP mutations
Deoxyribonucleic acid (DNA) was extracted using the 
QIAamp DNA MiniKit (Qiagen, Valencia, CA, USA) 
from pituitary adenoma tissue according to the manu-
facturer’s protocol. The entire coding sequence of 
AIP (NM_003977.2), the conserved splice sites (from 
the conserved A of the upstream branch site to +10 
downstream of each exon) and 1200 base pairs of the 
promoter region were directly sequenced, as described 
elsewhere (8). 
Assessment of SSTR2, SSTR5 and AIP expression 
levels
SSTR2, SSTR5 and AIP expression levels were analyzed 
by quantitative polymerase chain reaction (qPCR) 
u sing Taqman® methodology. Tumoral ribonucleic 
acid (RNA) was extracted using the RNeasy® Mini kit 
(Qiagen) according to the manufacturer’s protocol. 
The amount and quality of the extracted RNA were 
measured using NanoDrop 2000® (Thermo Fischer, 
Wilmington, DE, USA). The MultiScribeTM and High 
Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Carlsbad, CA, USA) were used for cDNA 
synthesis. 
Thermocycling and fluorescence detection were 
performed using Applied Biosystems 7500 Real-Time 
PCR System®. The thermal cycling profile consisted of a 
preincubation step of 50°C for 2 min and denaturation 
at 95°C for 10 min followed by 40 cycles of 95°C for 
15 seconds and 60°C for 1 min. In addition to SSTR2, 
SSTR5 and AIP, three housekeeping genes were ana-
lyzed [β-glucuronidase (GUSβ), TATA box-binding 
protein (TBP) and phosphoglycerate kinase 1 (PGK1)] as 
internal controls. Taqman® assays for each gene are de-
picted in table 1. Gene expression levels were calculated 
by QPCR software (14) using the efficiency of reaction 
(calculated for each reaction), and were compared with 
five normal pituitary tissues obtained from autopsies of 
subjects who had died of acute cardiovascular disease 
without evidence of previous endocrine disease. 
RESULTS
Analysis of AIP mutations
No somatic mutations in the AIP gene were identified 
in either patient.
Analysis of SSTR2, SSTR5 and AIP expression levels
The expression level of SSTR2 was high in both tu-
mors. The somatotropinoma of the patient 1 presented 
SSTR2 expression that was 15.51 times higher than 
that of normal pituitary tissue (NPT). The somatotro-
pinoma of the patient 2 presented SSTR2 expression 
that was 22.95 times higher than that of NPT. SSTR2 
expression level was 1.5 times higher in the adenoma 
of patient 2 compared with the adenoma of patient 1. 
SSTR5 expression was very low in both tumors in 
comparison with NPT. The somatotropinoma of the 
patient 2 presented expression 0.34 times that of NPT. 
SSTR5 expression level in the somatotropinoma of pa-
tient 1 was 0.11 times that of NPT.
AIP expression of the somatotropinoma of patient 
2 was similar to that of NPT (1.07x), while in patient 1, 
AIP expression level was 2.19 times higher than that of 
NPT. Comparing the two tumors, AIP expression was 
2.05 times higher in the tumor of patient 1. 
DISCUSSION
The commercially available SSAs enable the control of 
GH and IGF-I levels in approximately 30% of the ac-
romegalic patients (15,16). Considering their affinity 
to the five SSTRs, it is expected that the expression of 
SSTR2 is mandatory for good response to these drugs 
(3). Indeed, it has been demonstrated by our group and 
others, that disease activity is not controlled in the pres-
ence of low SSTR2 expression (4,5,17,18). However, 
the presence of a high SSTR2 expression is not invari-
ably associated with good response to SSAs therapy (5). 
In fact, a considerable proportion of patients with high 
SSTR2 expression do not achieve disease control with 
treatment, suggesting that other factors, such as SSTR5 
expression levels, the presence of truncated isoforms of 
this receptor, and alterations in post-receptor signal-
ing pathways may be involved (4,19). Our group has 
previously demonstrated, with another qPCR method 
(SYBR® Green), that the presence of a low SSTR2/
Table 3. Laboratory evaluation of patient 2
GH (ng/mL) IGF-I (ng/mL) NR: 101-267
Diagnosis 15.6 555
Post-surgery (3 months) 4.0 411
Octreotide LAR 20 mg (6 months) 5.39 304
Octreotide LAR 30 mg (6 months) 6.61 309
Values of growth hormone (GH) and insulin-like growth factor type I (IGF-I) at diagnosis, 
after surgery and after medical therapy in patient 2; NR: normal range.
AIP and octreotide LAR response
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SSTR5 ratio (lower than 1.3) was associated with worse 
response to SSAs therapy (4). 
Recent data have highlighted the importance of AIP 
expression in the response to SSAs therapy in acrome-
galy (9). Since the description of AIP germline muta-
tions in familial isolated pituitary adenomas, it has been 
observed that patients harboring these mutations have 
worse response to SSAs treatment (8,9,20). Indeed, 
a study that compared 96 acromegalic patients with 
germline AIP mutations and 232 matched controls 
(acromegalic patients without mutations) demonstrat-
ed that patients harboring AIP mutations had a poorer 
response to SSAs treatment (9). The AIP-mutated pa-
tients had smaller decreases in GH and IGF-I levels, 
as well as reduced tumor shrinkage, thereby indicating 
that AIP may play a role in the mechanism of response 
to SSAs (9). 
In addition to the data regarding familial acro-
megaly, it has been demonstrated that although no 
somatic mutation in the AIP gene has been found to 
date, a subset of sporadic somatotropinomas present 
low AIP expression (mainly the more invasive cases) 
(10,12,21). Our group has recently demonstrated 
that patients harboring tumors with low AIP protein 
expression have low chance of disea se control with 
OCT-LAR therapy, independent of SSTR2 expression 
(11). These data reinforce the importance of AIP ex-
pression for good response to SSAs treatment.
Direct evidence of AIP involvement in the 
mechanism(s) of action of SSAs was provided by a 
study of Chahal and cols. (13). These authors ob-
served that tumors from patients treated with lanreo-
tide before surgery exhibited higher AIP expression 
than tumors from patients treated primarily by sur-
gery. Furthermore, the authors performed an in vitro 
study and observed that treatment of GH3 cell lines 
with octreotide increased AIP expression. When AIP 
was knocked-down, the effect of octreotide in redu-
cing cell proliferation was attenuated, and this was 
likely mediated through modulation of the expression 
of the tumor suppressor zinc-finger protein ZAC1, 
whose expression is known to be essential for the anti-
proliferative effect of SSAs (13,22).
To illustrate these recent findings in the litera-
ture, we presented two cases of acromegalic patients 
who were not cured by surgery, were treated with 
OCT-LAR, and showed different responses to treat-
ment. In both cases, the tumors presented high SSTR2 
expression levels; however, patient 2 did not achieve 
disease control with OCT-LAR therapy despite having 
higher SSTR2 expression than patient 1. In both cases, 
low expression of SSTR5 was observed but, as previ-
ously described (4), it is the high expression of this re-
ceptor that is associated with poor response to octreo-
tide LAR. When we compared AIP expression levels of 
both tumors, we observed that AIP expression was two 
times higher in the somatotropinoma from the patient 
whose disease was controlled with medical treatment 
(case 1). As previously discussed, the presence of a high 
SSTR2 expression is not always associated with good 
response to SSAs treatment, as in patient 2. One of the 
possible explanations is lower AIP expression, as AIP 
appears to be important in the post-receptor signaling 
of SSAs drug therapy (13). 
The mechanism(s) of action of SSAs is not com-
pletely understood, and involves the regulation of ion 
channels (primarily potassium and calcium channels), 
adenylyl cyclase-cAMP-protein kinase A (PKA), mito-
gen-activated protein kinase (MAPK), and phospho-
tyrosine phosphatase (PTP) pathways (3). The exact 
place of AIP in this complex signaling machinery is not 
completely understood, and additional studies are nec-
essary to clarify this issue. 
One of the therapeutic possibilities for patient 2 
is to associate cabergoline to octreotide LAR, as this 
approach is effective in patients with mildly elevated 
IGF-I levels (23). There are no reports on the possible 
role of AIP expression as a predictor of response to ca-
bergoline in acromegaly, or if AIP is important in the 
mechanism of action of dopamine agonists. 
In conclusion, the cases reported here illustrate 
that, although the currently available SSAs bind pre-
ferentially to SSTR2, high expression of this receptor 
is not always associated with good response to thera-
py; high AIP expression may also be important for the 
mechanism of action of this drug class. 
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